Solid Biosciences Inc. earnings releases SLDB

Annual Quarterly

Solid Biosciences Inc. last reported quarterly results on Mar 6, 2026, for Q4 FY2025 (the quarter ended Dec 31, 2025): diluted EPS of -$0.53. It usually reports 8–65 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–65 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Mar 6, 2026 65 days after quarter end	Q4 FY2025 ended Dec 31, 2025	—	-50 -16.9%	-0.53 +47.3%
Nov 3, 2025 34 days after quarter end	Q3 FY2025 ended Sep 30, 2025	—	-46 -39.9%	-0.48 +39.2%
Feb 18, 2025 49 days after quarter end	Q4 FY2024 ended Dec 31, 2024	—	-43 -109.5%	-1.00 +0.8%
Jan 8, 2024 8 days after quarter end	— ended Dec 31, 2023	—	—	—
Jan 9, 2023 9 days after quarter end	— ended Dec 31, 2022	—	—	—
Aug 11, 2022 42 days after quarter end	— ended Jun 30, 2022	—	—	—
Apr 27, 2022 27 days after quarter end	— ended Mar 31, 2022	—	—	—
Jan 10, 2022 10 days after quarter end	— ended Dec 31, 2021	—	—	—

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: SLDB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Charlestown, MA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1707502
Former names: Solid Biosciences, LLC (until Jan 25, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.